Literature DB >> 25205550

Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma.

Yoshito Tomimaru1, Hiroshi Wada, Hidetoshi Eguchi, Akira Tomokuni, Naoki Hama, Koichi Kawamoto, Shigeru Marubashi, Koji Umeshita, Yuichiro Doki, Masaki Mori, Kenichi Wakasa, Hiroaki Nagano.   

Abstract

PURPOSE: The clinical significance of the surgical resection of metastatic lymph nodes (LN) from patients with hepatocellular carcinoma (HCC) remains controversial. The aim of this study was to evaluate the significance of the surgical resection of LN metastasis of HCC.
METHODS: Among 961 patients who underwent surgical resection for HCC in our hospital, LN metastasis was identified in 38 patients. In these patients, the metastatic LN were removed completely in 22 patients (complete removal group), and incompletely or not removed in 16 patients (control group). The long-term prognosis after LN metastasis was compared between the two groups.
RESULTS: The overall survival rate after LN metastasis was significantly better in the complete removal group (1-, 3- and 5-year: 71.2, 58.0 and 49.7%, respectively) than in the control group (45.9, 23.0 and 15.3%, respectively, p = 0.0477). LN metastasis was not the cause of death in any of the patients in the complete removal group, whereas it was a cause in some patients in the control group. No local LN recurrence was identified in the complete removal group.
CONCLUSIONS: The present results suggest that the complete removal of metastatic LN from HCC is clinically beneficial in selected patients.

Entities:  

Mesh:

Year:  2014        PMID: 25205550     DOI: 10.1007/s00595-014-1028-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  33 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Hepatoma presenting as a right atrial mass.

Authors:  D L Miller; N M Katz; R S Pallas
Journal:  Am Heart J       Date:  1987-10       Impact factor: 4.749

3.  Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

Authors:  Masato Sakon; Hiroaki Nagano; Keizo Dono; Shoji Nakamori; Koji Umeshita; Akira Yamada; Sumio Kawata; Yasuharu Imai; Shohei Iijima; Morito Monden
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

4.  Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases.

Authors:  J Watanabe; O Nakashima; M Kojiro
Journal:  Jpn J Clin Oncol       Date:  1994-02       Impact factor: 3.019

5.  Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases.

Authors:  K Yuki; S Hirohashi; M Sakamoto; T Kanai; Y Shimosato
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

6.  Clinical characteristics of hepatocellular carcinoma with an extensive lymph node metastasis at diagnosis.

Authors:  Tatsuya Abe; Junji Furuse; Masahiro Yoshino; Taira Kinoshita; Masaru Konishi; Kazuto Inoue; Takahiro Hasebe
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

7.  Case report: multiple systemic lymph node metastases from a small hepatocellular carcinoma.

Authors:  H Toyoda; Y Fukuda; Y Koyama; D Nishimura; H Hoshino; N Katada; K Kato; T Hayakawa
Journal:  J Gastroenterol Hepatol       Date:  1996-10       Impact factor: 4.029

8.  A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.

Authors:  Masato Nakamura; Hiroaki Nagano; Hiroshi Wada; Takehiro Noda; Hideo Ota; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Morito Monden
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

9.  Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.

Authors:  Hiroaki Nagano; Atsushi Miyamoto; Hiroshi Wada; Hideo Ota; Shigeru Marubashi; Yutaka Takeda; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

10.  Cytoreductive surgery for hepatocellular carcinoma.

Authors:  W Y Lau; T W Leung; K L Leung; S Ho; N Leung; M Chan; J Lin; A K Li
Journal:  Surg Oncol       Date:  1994-06       Impact factor: 3.279

View more
  6 in total

1.  The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy.

Authors:  Daisaku Yamada; Hidetoshi Eguchi; Tadafumi Asaoka; Hideo Tomihara; Takehiro Noda; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2017-04-18       Impact factor: 2.549

2.  Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells.

Authors:  Yusuke Matsuura; Hiroshi Wada; Hidetoshi Eguchi; Kunihito Gotoh; Shogo Kobayashi; Mitsuru Kinoshita; Masahiko Kubo; Koji Hayashi; Yoshifumi Iwagami; Daisaku Yamada; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2018-11-22       Impact factor: 3.199

3.  Our technique of preceding diaphragm resection and partial mobilization of the hepatic right lobe using a vessel sealing device (LigaSure™) for huge hepatic tumors with diaphragm invasion.

Authors:  Kenji Wakayama; Toshiya Kamiyama; Hideki Yokoo; Tatsuhiko Kakisaka; Tatsuya Orimo; Shingo Shimada; Yosuke Tsuruga; Hirofumi Kamachi; Akinobu Taketomi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

4.  The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.

Authors:  Yukiyasu Okamura; Ryo Ashida; Takaaki Ito; Teiichi Sugiura; Keita Mori; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2014-12-20       Impact factor: 2.549

5.  Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells.

Authors:  Reishi Toshiyama; Masamitsu Konno; Hidetoshi Eguchi; Hiroyasu Takemoto; Takehiro Noda; Ayumu Asai; Jun Koseki; Naotsugu Haraguchi; Yuji Ueda; Katsunori Matsushita; Kei Asukai; Tomofumi Ohashi; Yoshifumi Iwagami; Daisaku Yamada; Daisuke Sakai; Tadafumi Asaoka; Toshihiro Kudo; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Taroh Satoh; Yuichiro Doki; Nobuhiro Nishiyama; Masaki Mori; Hideshi Ishii
Journal:  Oncogene       Date:  2018-08-08       Impact factor: 9.867

6.  A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.

Authors:  Masafumi Yamashita; Hiroshi Wada; Hidetoshi Eguchi; Hisataka Ogawa; Daisaku Yamada; Takehiro Noda; Tadafumi Asaoka; Koichi Kawamoto; Kunihito Gotoh; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Int J Oncol       Date:  2016-04-25       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.